CN117357545A - 甘草酸苷在制备治疗万古霉素引起肾损伤药物中的应用 - Google Patents
甘草酸苷在制备治疗万古霉素引起肾损伤药物中的应用 Download PDFInfo
- Publication number
- CN117357545A CN117357545A CN202311222893.XA CN202311222893A CN117357545A CN 117357545 A CN117357545 A CN 117357545A CN 202311222893 A CN202311222893 A CN 202311222893A CN 117357545 A CN117357545 A CN 117357545A
- Authority
- CN
- China
- Prior art keywords
- vancomycin
- group
- kidney injury
- glycyrrhizin
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 title claims abstract description 58
- 108010059993 Vancomycin Proteins 0.000 title claims abstract description 52
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 title claims abstract description 52
- 229960003165 vancomycin Drugs 0.000 title claims abstract description 52
- 239000004378 Glycyrrhizin Substances 0.000 title claims abstract description 35
- 206010061481 Renal injury Diseases 0.000 title claims abstract description 35
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 title claims abstract description 35
- 229960004949 glycyrrhizic acid Drugs 0.000 title claims abstract description 35
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 title claims abstract description 35
- 235000019410 glycyrrhizin Nutrition 0.000 title claims abstract description 35
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 title claims abstract description 35
- 208000037806 kidney injury Diseases 0.000 title claims abstract description 34
- 239000003814 drug Substances 0.000 title claims description 9
- 229940079593 drug Drugs 0.000 title description 6
- 238000002360 preparation method Methods 0.000 title description 2
- 201000011040 acute kidney failure Diseases 0.000 claims description 33
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 27
- 208000033626 Renal failure acute Diseases 0.000 claims description 27
- 230000000694 effects Effects 0.000 abstract description 9
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 abstract description 6
- 239000003963 antioxidant agent Substances 0.000 abstract description 4
- 230000003078 antioxidant effect Effects 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 3
- 210000004926 tubular epithelial cell Anatomy 0.000 abstract description 3
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 230000030833 cell death Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 41
- 230000006378 damage Effects 0.000 description 21
- 210000003734 kidney Anatomy 0.000 description 19
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 14
- 230000001575 pathological effect Effects 0.000 description 11
- 230000003907 kidney function Effects 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 8
- 210000005084 renal tissue Anatomy 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 229940109239 creatinine Drugs 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000011725 BALB/c mouse Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 3
- 210000005239 tubule Anatomy 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000007119 pathological manifestation Effects 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- 208000014912 Central Nervous System Infections Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 101710118178 Protein Tube Proteins 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003589 nefrotoxic effect Effects 0.000 description 1
- 231100000381 nephrotoxic Toxicity 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000010024 tubular injury Effects 0.000 description 1
- 208000037978 tubular injury Diseases 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明通过实验证明甘草酸苷具有治疗肾损伤作用,特别是万古霉素导致肾损伤。甘草酸苷具有抗炎、抗氧化应激作用。甘草酸苷可能通过抗氧化应激作用,抑制万古霉素导致的肾小管上皮细胞死亡,从而发挥保护作用。
Description
技术领域
本发明涉及医药领域,具体涉及甘草酸苷在制备治疗万古霉素引起的肾损伤药物中的应用。
背景技术
万古霉素是临床常用的糖肽类抗菌药物,对多种革兰阳性菌有杀菌活性,用于多种敏感菌引起的感染,广泛应用于敏感菌引起的呼吸系统感染、中枢神经系统感染、血流感染等多种感染。它是世界三大感染顽疾之一——耐甲氧西林金黄色葡萄球菌感染的首选药。
但是万古霉素的缺点十分明显,具有明显的肾毒性。万古霉素导致急性肾损伤,造成巨大医疗负担,减少部分患者的救治机会,限制了其临床应用。
多种原因可导致肾损伤,其中药物性肾损伤是肾损伤的重要组成部分。不同药物导致的肾损伤在用药特点、损伤发生时间、损伤病理机制、治疗原则等方面存在诸多差异。万古霉素用药疗程为1-2周,甚至更长;导致肾损伤特点为急性肾损伤,一般发生在用药后的4-17天,损伤程度与万古霉素的剂量和疗程相关。万古霉素可能通过直接肾小管毒性、间质炎症、阻塞性小管铸型形成等多种机制导致肾损伤,其中阻塞性小管铸型形成是万古霉素肾损伤特有的机制。其他肾毒性药物也可导致肾损伤,如对比剂肾损伤为1次用药后导致急性肾损伤,一般在用药后3天内发生肾损伤;损伤机制主要与髓质缺血缺氧有关,因此临床上水化疗法可以有效的预防和降低对比剂肾损伤。均不同于万古霉素导致的肾损伤。
目前尚无可应用于临床的降低万古霉素肾损伤的保护剂,探索降低万古霉素肾损伤保护剂具有重要的临床意义。
发明内容
为克服现有技术缺陷,本发明提供了以下技术方案:
本发明提供了甘草酸苷在制备治疗肾损伤药物中的应用;
进一步的,所述肾损伤为万古霉素引起的肾损伤;
更进一步的,所述肾损伤为万古霉素引起的急性肾损伤;
附图说明
图1表示不同模型小鼠体重随时间变化情况。
图2表示不同模型小鼠肾脏损伤情况肉眼观察情况。
图3表示不同模型小鼠肾脏组织苏木精-伊红(Hematoxylin-eosin staining,HE)染色及肾损伤程度病理评分情况。
图4表示不同模型小鼠肾脏功能生物标志物情况。
有益效果
本发明通过实验证明甘草酸苷具有治疗肾损伤作用,特别是万古霉素导致肾损伤。甘草酸苷具有抗炎、抗氧化应激作用。甘草酸苷可能通过抗氧化应激作用,抑制万古霉素导致的肾小管上皮细胞死亡,从而发挥保护作用。
具体实施方式
本发明使用试剂均为常规市售。
实施例
1.实验方法:
(1)构建万古霉素导致急性肾损伤小鼠模型。BALB/c小鼠,腹腔注射万古霉素400mg/kg/天,持续7天,即可构建万古霉素肾损伤模型。
(2)甘草酸苷对正常小鼠肾功能的影响。BALB/c小鼠给予甘草酸苷高剂量200mg/kg,连续给药7天后处死小鼠,取血、静置4小时后离心、取上层血清,冻-80℃,测相应肾功能标志物,包括血清肌酐(Serum creatinine,SCr)和血尿素氮(Blood urea nitrogen,BUN)。取小鼠肾脏、纵半切、石蜡包埋、HE染色,在光镜下观察肾脏组织病理形态学变化,并进行损伤程度评分。评分方法:对显微镜下不同视野下的肾小管坏死、上皮损伤、扩张和管型形成进行评分,评价肾小管损伤程度。对肿胀、蛋白管型、空泡变性等病理改变采用0到3的数值分级评分。0,1,2,3级分别表示无明显病理改变、轻度病变(损伤程度≤25%)、轻度多灶性病变(损伤程度26-50%)、中重度病变(≥51%)。以此评估甘草酸苷对正常小鼠肾脏的影响。
(3)不同剂量甘草酸苷与万古霉素同时给药,观察甘草酸苷对万古霉素肾损伤的保护作用。BALB/c小鼠构建万古霉素导致急性肾损伤模型:腹腔注射万古霉素400mg/kg/天,持续7天。36只BALB/c小鼠,每组6只,共6组。分别为①对照组(给予生理盐水);②万古霉素导致急性肾损伤组(腹腔注射万古霉素400mg/kg/天,持续7天);③甘草酸苷高剂量组:200mg/kg;④甘草酸苷低剂量+万古霉素导致急性肾损伤组(于万古霉素前1小时给予腹腔注射甘草酸苷50mg/kg/天,7d);⑤甘草酸苷中剂量+万古霉素导致急性肾损伤(于VCM前1h给予腹腔注射GC 100mg/kg/天,7d);⑥甘草酸苷高剂量+万古霉素导致急性肾损伤(于VCM前1h给予腹腔注射GC 200mg/kg/天,7d)。连续给药7天后处死小鼠,取血、静置4小时后离心、取上层血清,冻-80℃,测相应肾功能标志物,包括血清肌酐和血尿素氮。取小鼠肾脏、纵半切、石蜡包埋、HE染色,在光镜下观察肾脏组织病理形态学变化,并进行损伤程度评分。以此评估甘草酸苷对正常小鼠肾脏的影响,以及不同剂量甘草酸苷对万古霉素肾损伤的保护作用。
(4)实验结果:
a.如图1所示,表示不同模型小鼠体重随时间变化情况。图中各组表示的含义:正常对照组(NC组);单用高剂量甘草酸苷组(GC alone(H)组);万古霉素导致急性肾损伤组(VI-AKI组);甘草酸苷低剂量+万古霉素导致急性肾损伤组(VAN+GC(L)组);甘草酸苷中剂量+万古霉素导致急性肾损伤组(VAN+GC(M)组);甘草酸苷高剂量+万古霉素导致急性肾损伤(VAN+GC(H)组)。相比于NC组,GC alone(H)组对小鼠体重没有影响,VI-AKI组小鼠体重显著减轻。相比于VI-AKI组,不同剂量GC+VI-AKI组的小鼠体重明显较重,且随着GC剂量的增加,小鼠体重增加呈剂量依赖性。该结果提示:GC本身不会导致小鼠体重减轻,万古霉素导致肾损伤与小鼠体重减轻相关,GC可剂量依赖性的改善万古霉素肾损伤小鼠体重减轻。
b.如图2所示,表示不同模型小鼠肾脏损伤情况肉眼观察情况。图中各组表示的含义:正常对照组(NC组);单用高剂量甘草酸苷组(GC alone(H)组);万古霉素导致急性肾损伤组(VI-AKI组);甘草酸苷低剂量+万古霉素导致急性肾损伤组(VAN+GC(L)组);甘草酸苷中剂量+万古霉素导致急性肾损伤组(VAN+GC(M)组);甘草酸苷高剂量+万古霉素导致急性肾损伤组(VAN+GC(H)组)。肉眼可见NC组小鼠肾脏呈现充盈的深红色,无异常表现。GCalone(H)组小鼠肾脏无明显异常表现。VI-AKI组小鼠肾脏呈现不充盈的苍白色,损伤明显。不同剂量GC+VI-AKI组的小鼠肾脏颜色呈现一定的程度的变白,随着GC剂量的增加,变白程度逐渐减轻。该结果提示:GC本身不会导致小鼠肾脏损伤,万古霉素会导致明显的肾脏损伤,GC可剂量依赖性的改善万古霉素导致的鼠肾损伤。
c.如图3所示,表示不同模型小鼠肾脏组织HE染色及肾损伤程度病理评分情况。图3a表示不同模型小鼠肾脏组织HE染色结果,图3b表示不同模型小鼠肾脏组织损伤程度病理评分情况。图中各组表示的含义正常对照组(NC组);单用高剂量甘草酸苷组(GC alone(H)组);万古霉素导致急性肾损伤组(VI-AKI组);甘草酸苷低剂量+万古霉素导致急性肾损伤组(VAN+GC(L)组);甘草酸苷中剂量+万古霉素导致急性肾损伤组(VAN+GC(M)组);甘草酸苷高剂量+万古霉素导致急性肾损伤组(VAN+GC(H)组)。
图3a显示,NC组小鼠肾脏肾小球和肾小管形态正常、结构清晰,无异常病理表现。GC alone(H)组小鼠肾脏无异常病理表现。VI-AKI组小鼠肾脏损伤明显:肾小管出现不同程度的变性和坏死,肾小管上皮细胞崩解、脱落及空泡变性,肾小管内偶见透明管型、肾小管基底膜增厚,炎性细胞呈多灶性浸润。肾间质出现严重水肿、大量嗜酸性粒细胞和中性粒细胞浸润,引起肾小管-间质性肾炎。不同剂量GC+VI-AKI组的小鼠肾脏呈一定程度的病理损伤,随着GC剂量的增加,损伤逐渐减轻。
图3b显示,相比于NC组,GC alone(H)组小鼠肾脏组织损伤评分结果无差异,VI-AKI组小鼠肾脏组织损伤评分显著升高。相比于VI-AKI组,不同剂量GC+VI-AKI组的小鼠肾脏病理损伤程度评分显著更低,且随着GC剂量的增加,小鼠肾脏病理损伤程度评分呈剂量依赖性降低。
图3通过小鼠肾脏HE染色结果及肾脏病理损伤程度评分结果显示:GC本身不会导致小鼠肾脏病理损伤,万古霉素会导致明显的肾脏损伤,GC可剂量依赖性的改善万古霉素导致的鼠肾损伤。
d.如图4所示,表示不同模型小鼠肾脏功能生物标志物情况。正常对照组(NC组);单用高剂量甘草酸苷组(GC alone(H)组);万古霉素导致急性肾损伤组(VI-AKI组);甘草酸苷低剂量+万古霉素导致急性肾损伤组(VAN+GC(L)组);甘草酸苷中剂量+万古霉素导致急性肾损伤(VAN+GC(M)组);甘草酸苷高剂量+万古霉素导致急性肾损伤(VAN+GC(H)组)。
图4a、4b分别表示不同模式下小鼠肾功能标志物血清肌酐、血尿素氮结果。
图4a结果显示:相比于NC组,GC alone(H)组的小鼠血清肌酐没有显著差异,VI-AKI组小鼠血清肌酐显著增高。相比于VI-AKI组,低剂量GC+VI-AKI组和中剂量GC+VI-AKI组小鼠血清肌酐没有显著差异,高剂量GC+VI-AKI组小鼠血清肌酐显著降低。
图4b结果显示:相比于NC组,GC alone(H)组小鼠血尿素氮没有显著差异,VI-AKI组小鼠血尿素氮显著增高。相比于VI-AKI组,不同剂量GC+VI-AKI组小鼠血尿素氮显著降低,且随着GC剂量的增加,血尿素氮降低呈剂量依赖性趋势。
图4结果显示,相比于NC组,GC alone(H)组小鼠肾功能标志物没有显著差异,VI-AKI组小鼠肾功能标志物显著增高。相比于VI-AKI组,GC+VI-AKI组小鼠肾功能标志物显著降低,且随着GC剂量的增加,肾功能标志物降低呈剂量依赖性趋势。
以上所述为本发明的较佳实施例而已,但本发明不应该局限于该实施例所公开的内容。所以凡是不脱离本发明所公开的精神下完成的等效或修改,都落入本发明保护的范围。
Claims (3)
1.甘草酸苷在制备治疗肾损伤药物中的应用。
2.根据权利要求1所述的应用,其特征在于,所述肾损伤为万古霉素引起的肾损伤。
3.根据权利要求2所述的应用,其特征在于,所述肾损伤为万古霉素引起的急性肾损伤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311222893.XA CN117357545A (zh) | 2023-09-20 | 2023-09-20 | 甘草酸苷在制备治疗万古霉素引起肾损伤药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311222893.XA CN117357545A (zh) | 2023-09-20 | 2023-09-20 | 甘草酸苷在制备治疗万古霉素引起肾损伤药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117357545A true CN117357545A (zh) | 2024-01-09 |
Family
ID=89404916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311222893.XA Pending CN117357545A (zh) | 2023-09-20 | 2023-09-20 | 甘草酸苷在制备治疗万古霉素引起肾损伤药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117357545A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106539803A (zh) * | 2016-12-13 | 2017-03-29 | 安徽医科大学 | 18β‑甘草次酸(或盐)作为减轻化疗药顺铂引起的急性肾损伤的辅助治疗药物的应用 |
CN107281205A (zh) * | 2017-07-06 | 2017-10-24 | 中国药科大学 | 异甘草酸镁在制备改善氨基糖苷类抗生素引起的肾损伤的治疗药物中的应用 |
-
2023
- 2023-09-20 CN CN202311222893.XA patent/CN117357545A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106539803A (zh) * | 2016-12-13 | 2017-03-29 | 安徽医科大学 | 18β‑甘草次酸(或盐)作为减轻化疗药顺铂引起的急性肾损伤的辅助治疗药物的应用 |
CN107281205A (zh) * | 2017-07-06 | 2017-10-24 | 中国药科大学 | 异甘草酸镁在制备改善氨基糖苷类抗生素引起的肾损伤的治疗药物中的应用 |
Non-Patent Citations (4)
Title |
---|
EUN-JIN SOHN等: "Protective Effects of Glycyrrhizin on Gentamicin-Induced Acute Renal Failure in Rats", PHARMACOLOGY & TOXICOLOGY, vol. 93, 31 December 2003 (2003-12-31), pages 116 * |
宋丽华: "《药物毒理学》", 31 January 2016, 中国医药科技出版社, pages: 47 - 48 * |
张明发等: "甘草酸对肾损伤的保护作用和临床应用研究进展", 现代药物与临床, vol. 27, no. 6, 30 November 2012 (2012-11-30), pages 655 - 659 * |
彭忠;李兴泉;李开龙;: "甘草酸18α体辅助治疗阿昔洛韦致急性肾衰竭73例", 重庆医学, no. 36, 30 December 2011 (2011-12-30), pages 3694 - 3695 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002532432A (ja) | 脳虚血の処置法及び脳虚血の処置のためのエリスロポエチン又はエリスロポエチン誘導体類の使用 | |
CN117357545A (zh) | 甘草酸苷在制备治疗万古霉素引起肾损伤药物中的应用 | |
CN113209117A (zh) | 一种治疗酒精性脂肪肝和酒精性肝纤维化的药物 | |
US7470666B2 (en) | Use of Ulinastatin and its pharmaceutical composition for treating severe acute respiratory syndrome | |
CN109730983A (zh) | 丹叶大黄素在制备治疗脓毒症药物中的应用 | |
CN113209088B (zh) | 硫藤黄菌素在保护非酒精性脂肪性肝炎中的应用 | |
EP2606883A1 (en) | Uses of n-Butylidenephthalide in Treating a Liver Injury and Improving Liver Function | |
DE602004012152T2 (de) | Verwendung von cystin oder cystein zur vorbeugung und behandlung von oxidativem stress hervorgerufen durch hämodialyse bei patienten mit chronischen nierenerkrankungen | |
CN112569222A (zh) | 三氟淫羊藿素在制备改善疼痛、肿胀及运动功能的药物中的应用 | |
CN113827587A (zh) | 丹酚酸a在制备预防血栓性脑缺血的药物中的应用 | |
CN1186068C (zh) | 具有消炎生肌止痒止痛作用的外用中成药及其制备方法 | |
CN113813365B (zh) | 太子参环肽b在制备抗溃疡性结肠炎药物中的应用 | |
CN112022865B (zh) | 白头翁皂苷b4在制备治疗糖尿病皮肤溃疡的药物中的用途 | |
CN112716960A (zh) | 甘草次酸在制备治疗肾小管间质炎症药物中的应用 | |
JP7228895B2 (ja) | 敗血症の予防又は治療用組成物 | |
CN112870225B (zh) | 一种用于高危急性早幼粒细胞白血病诱导期的联合治疗药物 | |
CN112535682B (zh) | 一种沙尔威酮衍生物在药物制备中的应用 | |
CN103599105B (zh) | Caesanines D在制备治疗急性肾衰药物中的应用 | |
CN116196394A (zh) | 重组人Matrilin-3蛋白在制备治疗脑血管疾病的药物中的应用 | |
Sayed et al. | ANTIMICROBIAL ACTIVITY OF SOME NATURAL PRODUCT AGAINST INFECTED WOUND IN RAT MODEL WITH MDR | |
CN116036106A (zh) | 一种治疗淋巴水肿的药物运用 | |
CN116327776A (zh) | 酮康唑软膏及酮康唑软膏类似物治疗复发性口腔炎的用途 | |
CN118001375A (zh) | 一种用于难愈性创面修复的药物 | |
CN110974904A (zh) | 注射用益气复脉(冻干)的医药用途 | |
CN117427099A (zh) | 豨莶草提取物在特应性皮炎中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |